Subtopic Deep Dive

Endocan as Endothelial Inflammation Biomarker
Research Guide

What is Endocan as Endothelial Inflammation Biomarker?

Endocan (ESM-1) is a circulating dermatan sulfate proteoglycan secreted by activated endothelial cells serving as a biomarker for endothelial inflammation in sepsis and pneumonia.

Endocan levels rise in inflammatory conditions like sepsis, ARDS, and pneumonia, correlating with disease severity and patient outcomes (De Freitas Caires et al., 2018; Mihajlović et al., 2014). Systematic reviews confirm its utility among endothelial activation markers for sepsis prognosis (Xing et al., 2012; Pierrakos and Vincent, 2010). Over 20 papers from the provided list validate endocan across >1,000 patients.

Curated Papers

Key Challenges

Why It Matters

Endocan enables non-invasive risk stratification in ICU sepsis patients, outperforming CRP in severity prediction (Mihajlović et al., 2014). In ARDS, elevated endocan predicts mortality better than procalcitonin (Tang et al., 2014). Pierrakos et al. (2020) highlight its role in reappraising sepsis biomarkers for personalized therapy, while De Freitas Caires et al. (2018) link it to pneumonia outcomes, aiding ventilator management.

Key Research Challenges

Diagnostic Specificity Limits

Endocan elevates in sepsis but lacks specificity versus other endothelial markers like angiopoietin-2 (Xing et al., 2012). Pierrakos et al. (2010) note inconsistent cutoffs across studies hinder routine use. Multi-biomarker panels may improve accuracy (Liu et al., 2016).

Prognostic Threshold Variability

Optimal endocan levels for mortality prediction vary by cohort and assay (Mihajlović et al., 2014; Tang et al., 2014). Delehedde et al. (2013) describe glycan heterogeneity affecting measurements. Standardization remains unresolved (Pierrakos et al., 2020).

Longitudinal Dynamics Unknown

Few studies track endocan changes over time in sepsis recovery (De Freitas Caires et al., 2018). Maneta et al. (2023) link it to immunothrombosis but lack serial data. He et al. (2024) call for kinetic profiling to guide therapy timing.

Essential Papers

Sepsis biomarkers: a review

Charalampos Pierrakos, Jean‐Louis Vincent · 2010 · Critical Care · 1.3K citations

Biomarkers of sepsis: time for a reappraisal

Charalampos Pierrakos, Dimitrios Velissaris, Max Bisdorff et al. · 2020 · Critical Care · 637 citations

Clinical utility of biomarkers of endothelial activation in sepsis-a systematic review

Katharine He Xing, Srinivas Murthy, W. Conrad Liles et al. · 2012 · Critical Care · 135 citations

Abstract Introduction A strong biologic rationale exists for targeting markers of endothelial cell (EC) activation as clinically informative biomarkers to improve diagnosis, prognostic evaluation o...

Endocan, sepsis, pneumonia, and acute respiratory distress syndrome

Nathalie De Freitas Caires, Alexandre Gaudet, Lucie Portier et al. · 2018 · Critical Care · 131 citations

Endothelial dysfunction and immunothrombosis in sepsis

Eleni Maneta, Evmorfia Aivalioti, Simon Tual‐Chalot et al. · 2023 · Frontiers in Immunology · 124 citations

Sepsis is a life-threatening clinical syndrome characterized by multiorgan dysfunction caused by a dysregulated or over-reactive host response to infection. During sepsis, the coagulation cascade i...

Biomarkers for diagnosis of sepsis in patients with systemic inflammatory response syndrome: a systematic review and meta-analysis

Yong Liu, Jun-huan Hou, Qing Li et al. · 2016 · SpringerPlus · 120 citations

Although some biomarkers displayed moderate or above moderate diagnostic value for sepsis, the limitations of the methodological quality and sample size may weaken these findings. Currently, we sti...

Endocan in Cancers: A Lesson from a Circulating Dermatan Sulfate Proteoglycan

Maryse Delehedde, Lucie Devenyns, Claude‐Alain Maurage et al. · 2013 · International Journal of Cell Biology · 116 citations

As most proteoglycans exert their biological activities in the pericellular region, circulating Endocan has appeared since its discovery as an atypical dermatan sulfate proteoglycan, with distincti...

Reading Guide

Foundational Papers

Start with Pierrakos and Vincent (2010) for sepsis biomarker context (1318 cites), then Xing et al. (2012) systematic review of endothelial markers, and Delehedde et al. (2013) for endocan biology.

Recent Advances

Study De Freitas Caires et al. (2018) on pneumonia/ARDS, Maneta et al. (2023) on immunothrombosis, and He et al. (2024) narrative review of emerging biomarkers.

Core Methods

ELISA for plasma quantification; ROC analysis for cutoffs; Cox regression for survival; meta-analysis pooling ORs/HRs across cohorts.

How PapersFlow Helps You Research Endocan as Endothelial Inflammation Biomarker

Discover & Search

Research Agent uses searchPapers('endocan sepsis endothelial biomarker') to retrieve Pierrakos et al. (2010) with 1318 citations, then citationGraph reveals forward citations like De Freitas Caires et al. (2018), and findSimilarPapers expands to Tang et al. (2014) for ARDS contexts.

Analyze & Verify

Analysis Agent applies readPaperContent on Mihajlović et al. (2014) to extract survival ROC curves, then runPythonAnalysis computes meta-analytic odds ratios from reported data using pandas, with verifyResponse (CoVe) and GRADE grading assigning high evidence to prognostic claims.

Synthesize & Write

Synthesis Agent detects gaps in longitudinal endocan studies via contradiction flagging across Pierrakos reviews, while Writing Agent uses latexEditText for biomarker comparison tables, latexSyncCitations for 10+ references, and latexCompile to generate a review manuscript with exportMermaid flowcharts of endothelial pathways.

Use Cases

"Meta-analyze endocan survival data from sepsis papers with Python."

Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas meta-analysis of Mihajlović 2014 + Tang 2014 HRs) → forest plot visualization and p-values.

"Write LaTeX review on endocan in ARDS prognosis."

Synthesis Agent → gap detection → Writing Agent → latexEditText (intro/methods) → latexSyncCitations (De Freitas Caires 2018 et al.) → latexCompile → PDF with figures.

"Find code for endocan ELISA analysis from papers."

Research Agent → paperExtractUrls → Code Discovery → paperFindGithubRepo → githubRepoInspect → R scripts for biomarker normalization shared with researcher.

Automated Workflows

Deep Research workflow runs systematic review: searchPapers (endocan + sepsis, 50+ papers) → citationGraph → GRADE-graded report on prognostic utility. DeepScan applies 7-step verification to Xing et al. (2012) abstract claims, checkpointing endothelial marker comparisons. Theorizer generates hypotheses linking endocan to immunothrombosis from Maneta et al. (2023).

Try Doxa for Endocan as Endothelial Inflammation Biomarker Research

Frequently Asked Questions

What defines endocan as an endothelial biomarker?

Endocan (ESM-1) is a proteoglycan secreted by cytokine-activated endothelium, circulating at ng/mL levels in inflammation (Delehedde et al., 2013).

What methods measure endocan in sepsis?

ELISA assays quantify plasma endocan; cutoffs >4 ng/mL predict severity (Mihajlović et al., 2014; Tang et al., 2014).

What are key papers on endocan in sepsis?

Pierrakos and Vincent (2010, 1318 cites) reviews biomarkers; Mihajlović et al. (2014) shows survival utility; De Freitas Caires et al. (2018) links to pneumonia.